FDA Clears Haemonetics PerQseal Elite Vascular Closure System

Clinicaltrialvanguard reports that the FDA has cleared Haemonetics’ PerQseal Elite vascular closure system for large-bore arterial procedures. The reported regulatory action concerns the PerQseal Elite system and its use in the large-bore arterial procedure setting.

FDA clearance reported for PerQseal Elite

According to Clinicaltrialvanguard, the FDA clearance applies to the Haemonetics PerQseal Elite vascular closure system. The publisher identifies the system as a vascular closure option for large-bore arterial procedures.

The clearance is a regulatory update for professionals following devices used in arterial procedure workflows. Clinicaltrialvanguard’s report centers on the cleared PerQseal Elite system and the large-bore arterial setting named in the announcement.

For medical sales professionals, the news provides a current product-specific development to track in conversations involving vascular closure systems. Communications about the event can focus on the FDA clearance reported by Clinicaltrialvanguard and the large-bore arterial procedure context associated with the system.

Clinical trial result cited by the publisher

Clinicaltrialvanguard also reports that the clinical trial showed zero major complications. The publisher cites this result in connection with the PerQseal Elite vascular closure system and the FDA clearance news.

The reported trial outcome is distinct from the clearance itself. In reviewing the announcement, teams can separate the FDA action from the clinical-trial result while retaining the publisher’s stated context: a vascular closure system for large-bore arterial procedures.

Key points from the announcement

• Clinicaltrialvanguard reports FDA clearance for Haemonetics’ PerQseal Elite vascular closure system.
• The report identifies large-bore arterial procedures as the setting for the cleared system.
• Clinicaltrialvanguard states that the clinical trial showed zero major complications.

The announcement places Haemonetics’ PerQseal Elite system in focus as an FDA-cleared vascular closure system for the procedure setting reported by Clinicaltrialvanguard. Medical sales teams following regulatory developments can use the publisher’s report as the basis for monitoring this update.